Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?

Background: Intradetrusor injection of botulinum toxin A (BTX-A) might serve as a minimally invasive substitute in patients with refractory idiopathic overactive bladder (RIOAB). The aim of this study was to evaluate the clinical outcomes related to two different doses of abo-BTX-A (AboBTX-A) in patients with RIOAB. Materials and Methods: This prospective clinical trial was performed on 55 women with RIOAB. After determination of trabeculation grade, 300 (no or mild) or 500 (moderate or severe) unit of AboBTX-A (Dysport) was intravesicaly injected. Before 1, 3, and 6 months after intervention, lower urinary tract symptoms during 24 h were recorded. Results: Of the study population, 62% had severe bladder trabeculation. The mean duration of overactive bladder (OAB) was 1.76 versus 5.85 years, for no or mild versus severe trabeculation, respectively. After injections of 300- and 500-unit dosage, there were 19% and 26% early complications such as urinary retention. There was a statistically significant difference between the two groups in OAB score after 1 month (P < 0.001) and duration of OAB symptoms, over three follow-up times (P < 0.001). The mean preinjection OAB scores between patients with and without recurrence were statistically significant (29.36 vs. 25.07; P < 0.03). Urinary tract infection as a late complication was distinguished in four patients. Conclusion: In RIOAB, by adjusted dosage of AboBTX-A related to the grade of bladder trabeculation, in addition to maintain efficacy, consequent complications might not be affected by dosage and the drug dosage could be increased to nearly 60% with less concern associated to complication

[1]  N. Osman,et al.  The underactive bladder: detection and diagnosis , 2016, F1000Research.

[2]  R. Onur,et al.  Role of percutaneous posterior tibial nerve stimulation either alone or combined with an anticholinergic agent in treating patients with overactive bladder. , 2015, Turkish journal of urology.

[3]  B. Vahdatpour,et al.  Potential risk factors associated with stress urinary incontinence among Iranian women , 2015, Advanced biomedical research.

[4]  M. Poli-Mérol,et al.  Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. , 2014, Journal of pediatric surgery.

[5]  P. Abrams,et al.  New therapies in the treatment of overactive bladder , 2013, Expert opinion on emerging drugs.

[6]  F. Alizadeh,et al.  The role of pelvic organs prolapse in the etiology of urinary incontinence in women , 2013, Advanced biomedical research.

[7]  S. Mahajan,et al.  The use of botulinum toxin for the treatment of overactive bladder syndrome , 2013, Indian journal of urology : IJU : journal of the Urological Society of India.

[8]  S. Kenyon,et al.  Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). , 2012, European urology.

[9]  Z. Sheikhi,et al.  Effect of Botulinum neurotoxin type A injection in refractory idiopathic overactive bladder , 2011 .

[10]  L. Kavoussi,et al.  Campbell-Walsh Urology 10th Edition Review, 10th Edition , 2011 .

[11]  R. Dmochowski,et al.  Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. , 2010, The Journal of urology.

[12]  A. Kajbafzadeh,et al.  Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia. , 2010, Urology.

[13]  T. Kessler,et al.  Clean Intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections: Short-Term Effect on Quality of Life , 2009, Obstetrics and gynecology.

[14]  John T. Wei,et al.  Refractory idiopathic urge urinary incontinence and botulinum A injection. , 2008, The Journal of urology.

[15]  J. Rentería,et al.  Use of Botulinum Toxin Type A (Botox®) Through Transcystoscopic Vesical Insertion for Overactive Bladder Syndrome Non-Responsive to Oral Medication or for Parasympatholytic Drugs use Severe Side Effects , 2008 .

[16]  S. Shah,et al.  Intradetrusor botulinum toxin injections for overactive bladder , 2008 .

[17]  M. Fynes,et al.  Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity , 2007, BJU international.

[18]  C. Koh,et al.  Campbell-Walsh Urology, Volumes 1-4 , 2007 .

[19]  K. Moore,et al.  Extracorporeal magnetic stimulation is of limited clinical benefit to women with idiopathic detrusor overactivity: a randomized sham controlled trial. , 2007, European urology.

[20]  M. Chancellor,et al.  The overactive bladder: Epidemiology and morbidity. , 2006, The Urologic clinics of North America.

[21]  M. Chancellor,et al.  The case for bladder botulinum toxin application. , 2006, The Urologic clinics of North America.

[22]  Brian L. Cohen,et al.  Predictors of success for first stage neuromodulation: motor versus sensory response. , 2006, The Journal of urology.

[23]  C. Chapple,et al.  Botulinum toxin--new mechanisms, new therapeutic directions? , 2006, European urology.

[24]  A. Wein,et al.  Overactive bladder: a better understanding of pathophysiology, diagnosis and management. , 2006, The Journal of urology.

[25]  C. Chapple.  Interview with Chris Chapple. Overactive bladder: tackling the problem. , 2006, European urology.

[26]  D. Small,et al.  A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity , 2005, BJU international.

[27]  D. Schmid,et al.  Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. , 2005, American journal of obstetrics and gynecology.

[28]  J. Selander,et al.  Nocturia in relation to somatic health, mental health and pain in adult men and women , 2005, BJU international.

[29]  M. Fall,et al.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. , 2002 .

[30]  MJ Drake,et al.  Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function , 2001, The Lancet.

[31]  B. Schurch,et al.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. , 2000, The Journal of urology.

[32]  A. Elbadawi.  Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. II. Pathology and pathophysiology. , 1998, Urology.

[33]  A. B. Scott,et al.  Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. , 1988, The Journal of urology.